Skip to main content

Table 1 Analysis of IRX2 mRNA expression in primary breast tumors. IRX2 expression was determined in one large published expression data set [29] and correlated to the indicated clinico-pathological parameters

From: Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells

  IRX2 low IRX2 high P-value
n % n %
All patients 998 50.1 994 49.9 %  
Histology      <0.001
  Ductal 809 82.7 744 76.5
  Lobular 47 4.8 101 10.4
  Ductolobular 42 4.3 48 4.9
  Others 69 7.1 76 7.8
Tumor stage      0.004
  1 174 31.8 198 39.4
  2 308 56.2 271 53.9
  3 + 4 66 12.1 34 6.8
Grade      <0.001
  1 59 6.2 111 11.7
  2 352 36.9 423 44.7
  3 544 57.0 413 43.6
Lymph node status      0.044
  N0 503 50.4 546 54.9
  N+ 495 49.6 448 45.1
Tumor size      
  <2 cm 407 43.3 499 45.8 0.050
  >2 cm 578 58.7 532 54.2  
ER expression      0.001
  Negative 268 26.9 206 20.7
  Positive 730 73.1 788 79.3
PR expression      <0.001
  Negative 540 54.1 403 40.5
  Positive 458 45.9 591 59.5
HER2 expression      0.735
  Negative 876 87.8 867 87.2
  Positive 122 12.2 127 12.8
Subtype       <0.001
  Basal 206 20.7 125 12.6
  HER2 121 12.2 119 12.0
  LumA 303 30.5 418 42.2
  LumB 292 29.3 200 20.2
P53 mutation status      0.454
  Mutant 56 12.9 43 11.1
  wt 378 87.1 343 88.9